

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Gębicki *et al.*

Appl. No. 10/585,892;  
§ 371 Date: July 11, 2006

U.S. Nat'l Stage of PCT/EP05/50057;  
I.A. Fd: January 7, 2005

For: Use of Quaternary Pyridinium Salts  
as Vasoprotective Agents

Confirmation No. 7625

Art Unit: 1614

Examiner: Nelson Clarence Blakely III

Atty. Docket: 2782.0010001/MAC

**Reply To Second Restriction Requirement**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Madam Commissioner:

***Reply to the Restriction Requirement***

In reply to the Restriction Requirement dated January 29, 2009, Applicants hereby provisionally elect to prosecute the invention of **Group I**, represented by claims 57-64, 70-72, 74-80 and 86 (and by new claims 87-89, added by amendment herewith). This election is made without prejudice to or disclaimer of the other claims or inventions disclosed. This restriction of Groups I and II is made without traverse.

***Reply to the Election of Species***

In reply to the election of species requirement, Applicants elect the species of claim 63, i.e., the condition or disease of hypertriglyceridemia.